Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

Cancer drug resistance and epithelial-mesenchymal transition (EMT), a critical process of
cancer invasion and metastasis, have recently been associated with the existence of cancer …

Tyrosine kinase inhibitors currently confer the greatest survival gain for nonsmall cell lung
cancer (NSCLC) patients with actionable genetic alterations. Simultaneously, the increasing …

EGFR tyrosine kinase inhibitors cause dramatic responses in EGFR-mutant lung cancer, but
resistance universally develops. The involvement of β-catenin in EGFR TKI resistance has …

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal
growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R …

Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest morbidity and
leading cause of death worldwide, whereas its pathogenesis has not been fully elucidated …

Mammalian transducin-like enhancer of split family proteins (TLEs) are homologous to
Drosophila Groucho (Gro) and are essential transcriptional repressors. Seven TLE family …

Aberrant activation of EGFR represents a common event in non-small cell lung carcinoma
(NSCLC) and activates various downstream signaling pathways. While EGFR activation of β …

Upregulated Wnt/β-catenin signaling is associated with increased cancer cell resistance and
cancer cell-elicited immunosuppression. In non-neoplastic immune cells, upregulated Wnt/β …